154 related articles for article (PubMed ID: 35763178)
21. Salvage chemotherapy with paclitaxel, ifosfamide, and cisplatin (TIP) in relapsed or cisplatin-refractory germ cell tumors.
Park S; Lee S; Lee J; Park SH; Park JO; Kang WK; Park YS; Lim HY
Onkologie; 2011; 34(8-9):416-20. PubMed ID: 21934340
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of gemcitabine, oxaliplatin, and paclitaxel in cisplatin-refractory germ cell cancer in routine care--Registry data from an outcomes research project of the German Testicular Cancer Study Group.
Seidel C; Oechsle K; Lorch A; Dieing A; Hentrich M; Hornig M; Grünwald V; Cathomas R; Meiler J; de Wit M; Bokemeyer C
Urol Oncol; 2016 Apr; 34(4):167.e21-8. PubMed ID: 26699830
[TBL] [Abstract][Full Text] [Related]
23. Phase I/II study of sequential dose-intensified ifosfamide, cisplatin, and etoposide plus paclitaxel as induction chemotherapy for poor prognosis germ cell tumors by the German Testicular Cancer Study Group.
Hartmann JT; Gauler T; Metzner B; Gerl A; Casper J; Rick O; Horger M; Schleicher J; Derigs G; Mayer-Steinacker R; Beyer J; Kuczyk MA; Bokemeyer C;
J Clin Oncol; 2007 Dec; 25(36):5742-7. PubMed ID: 18089869
[TBL] [Abstract][Full Text] [Related]
24. Antitumoral activity of oxaliplatin/cisplatin-based combination therapy in cisplatin-refractory germ cell cancer patients.
Soulié P; Garrino C; Bensmaïne MA; Bekradda M; Brain E; Di Palma M; Goupil A; Misset JL; Cvitkovic E
J Cancer Res Clin Oncol; 1999 Dec; 125(12):707-11. PubMed ID: 10592105
[TBL] [Abstract][Full Text] [Related]
25. Activity of oxaliplatin in patients with relapsed or cisplatin-refractory germ cell cancer: a study of the German Testicular Cancer Study Group.
Kollmannsberger C; Rick O; Derigs HG; Schleucher N; Schöffski P; Beyer J; Schoch R; Sayer HG; Gerl A; Kuczyk M; Spott C; Kanz L; Bokemeyer C
J Clin Oncol; 2002 Apr; 20(8):2031-7. PubMed ID: 11956262
[TBL] [Abstract][Full Text] [Related]
26. Outcomes of Autologous Stem Cell Transplantation (ASCT) in Relapsed/Refractory Germ Cell Tumors: Single Center Experience from Turkey.
Yildiz F; Durnali A; Eraslan E; Ilhan A; Tufan G; Aslan F; Arslan UY; Alkis N; Demirci U; Altuntas F; Oksuzoglu B
Urol J; 2020 Aug; 17(5):497-500. PubMed ID: 32869258
[TBL] [Abstract][Full Text] [Related]
27. Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial.
Fizazi K; Pagliaro L; Laplanche A; Fléchon A; Mardiak J; Geoffrois L; Kerbrat P; Chevreau C; Delva R; Rolland F; Theodore C; Roubaud G; Gravis G; Eymard JC; Malhaire JP; Linassier C; Habibian M; Martin AL; Journeau F; Reckova M; Logothetis C; Culine S
Lancet Oncol; 2014 Dec; 15(13):1442-1450. PubMed ID: 25456363
[TBL] [Abstract][Full Text] [Related]
28. Gemcitabine in patients with relapsed or cisplatin-refractory testicular cancer.
Bokemeyer C; Gerl A; Schöffski P; Harstrick A; Niederle N; Beyer J; Casper J; Schmoll HJ; Kanz L
J Clin Oncol; 1999 Feb; 17(2):512-6. PubMed ID: 10080593
[TBL] [Abstract][Full Text] [Related]
29. Sequential versus single high-dose chemotherapy in patients with relapsed or refractory germ cell tumors: long-term results of a prospective randomized trial.
Lorch A; Kleinhans A; Kramar A; Kollmannsberger CK; Hartmann JT; Bokemeyer C; Rick O; Beyer J
J Clin Oncol; 2012 Mar; 30(8):800-5. PubMed ID: 22291076
[TBL] [Abstract][Full Text] [Related]
30. Phase II clinical trial of oxaliplatin and bevacizumab in refractory germ cell tumors.
Jain A; Brames MJ; Vaughn DJ; Einhorn LH
Am J Clin Oncol; 2014 Oct; 37(5):450-3. PubMed ID: 23388561
[TBL] [Abstract][Full Text] [Related]
31. Phase II trial of brentuximab vedotin in relapsed/refractory germ cell tumors.
Ashkar R; Feldman DR; Adra N; Zaid MA; Funt SA; Althouse SK; Perkins SM; Snow CI; Lazzara KM; Sego LM; Quinn DI; Hanna NH; Einhorn LH; Albany C
Invest New Drugs; 2021 Dec; 39(6):1656-1663. PubMed ID: 34031784
[TBL] [Abstract][Full Text] [Related]
32. Sequential high-dose chemotherapy protocol for relapsed poor prognosis germ cell tumors combining two mobilization and cytoreductive treatments followed by three high-dose chemotherapy regimens supported by autologous stem cell transplantation. Results of the phase II multicentric TAXIF trial.
Lotz JP; Bui B; Gomez F; Théodore C; Caty A; Fizazi K; Gravis G; Delva R; Peny J; Viens P; Duclos B; De Revel T; Curé H; Gligorov J; Guillemaut S; Ségura C; Provent S; Droz JP; Culine S; Biron P;
Ann Oncol; 2005 Mar; 16(3):411-8. PubMed ID: 15659420
[TBL] [Abstract][Full Text] [Related]
33. Four Cycles of Etoposide plus Cisplatin for Patients with Good-Risk Advanced Germ Cell Tumors.
Funt SA; McHugh DJ; Tsai S; Knezevic A; O'Donnell D; Patil S; Silber D; Bromberg M; Carousso M; Reuter VE; Carver BS; Sheinfeld J; Motzer RJ; Bajorin DF; Bosl GJ; Feldman DR
Oncologist; 2021 Jun; 26(6):483-491. PubMed ID: 33586274
[TBL] [Abstract][Full Text] [Related]
34. Treatment of relapsed/refractory germ cell tumours: an equipoise between conventional and high dose therapy.
Rashid S; Lim L; Powles T
Curr Treat Options Oncol; 2012 Jun; 13(2):201-11. PubMed ID: 22623055
[TBL] [Abstract][Full Text] [Related]
35. The efficacy of irinotecan, paclitaxel, and oxaliplatin (IPO) in relapsed germ cell tumours with high-dose chemotherapy as consolidation: a non-cisplatin-based induction approach.
Badreldin W; Krell J; Chowdhury S; Harland SJ; Mazhar D; Harding V; Frampton AE; Wilson P; Berney D; Stebbing J; Shamash J
BJU Int; 2016 Mar; 117(3):418-23. PubMed ID: 25430674
[TBL] [Abstract][Full Text] [Related]
36. Phase II study of cisplatin plus epirubicin salvage chemotherapy in refractory germ cell tumors.
Bedano PM; Brames MJ; Williams SD; Juliar BE; Einhorn LH
J Clin Oncol; 2006 Dec; 24(34):5403-7. PubMed ID: 17135640
[TBL] [Abstract][Full Text] [Related]
37. Single versus sequential high-dose chemotherapy in patients with relapsed or refractory germ cell tumors: a prospective randomized multicenter trial of the German Testicular Cancer Study Group.
Lorch A; Kollmannsberger C; Hartmann JT; Metzner B; Schmidt-Wolf IG; Berdel WE; Weissinger F; Schleicher J; Egerer G; Haas A; Schirren R; Beyer J; Bokemeyer C; Rick O;
J Clin Oncol; 2007 Jul; 25(19):2778-84. PubMed ID: 17602082
[TBL] [Abstract][Full Text] [Related]
38. Bevacizumab/high-dose chemotherapy with autologous stem-cell transplant for poor-risk relapsed or refractory germ-cell tumors.
Nieto Y; Tu SM; Bassett R; Jones RB; Gulbis AM; Tannir N; Kingham A; Ledesma C; Margolin K; Holmberg L; Champlin R; Pagliaro L
Ann Oncol; 2015 Oct; 26(10):2125-32. PubMed ID: 26199392
[TBL] [Abstract][Full Text] [Related]
39. Accelerated BEP for metastatic germ cell tumours: a multicenter phase II trial by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP).
Grimison PS; Stockler MR; Chatfield M; Thomson DB; Gebski V; Friedlander M; Boland AL; Houghton B; Gurney H; Rosenthal M; Singhal N; Kichenadasse G; Wong SS; Lewis CR; Vasey PA; Toner GC;
Ann Oncol; 2014 Jan; 25(1):143-8. PubMed ID: 24356625
[TBL] [Abstract][Full Text] [Related]
40. Weekly gemcitabine, paclitaxel, oxaliplatin combination chemotherapy in patients with Cisplatin-refractory germ cell tumor: preliminary experience.
De Giorgi U; Rosti G; Papiani G; Aieta M; Fochessati F; Paoluzzi L; Valduga F; Marangolo M
Am J Clin Oncol; 2004 Oct; 27(5):457-60. PubMed ID: 15596910
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
